| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943621 | ALLERGAN | Salts of piperazine compounds as D3/D2 antagonists |
Dec, 2028
(5 years from now) | |
| US7737142 | ALLERGAN | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists |
Sep, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47350 | ALLERGAN | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(5 years from now) | |
| USRE49110 | ALLERGAN | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(5 years from now) | |
Vraylar is owned by Allergan.
Vraylar contains Cariprazine Hydrochloride.
Vraylar has a total of 4 drug patents out of which 0 drug patents have expired.
Vraylar was authorised for market use on 17 September, 2015.
Vraylar is available in capsule;oral dosage forms.
Vraylar can be used as treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine; treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of schizophrenia with cariprazine, treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine; treatment of schizophrenia and/or acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of schizophrenia with cariprazine, treatment of schizophrenia and/or acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of schizophrenia with cariprazine; treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine.
The generics of Vraylar are possible to be released after 17 September, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 16, 2025 |
Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 September, 2015
Treatment: Treatment of schizophrenia and/or acute manic or mixed episodes associated with bipolar i disorder with cariprazine; Treatment of schizophrenia with cariprazine; Treatment of acute manic or mixed epis...
Dosage: CAPSULE;ORAL
VRAYLAR family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE49302 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(5 years from now) | |
Vraylar is owned by Abbvie.
Vraylar contains Cariprazine Hydrochloride.
Vraylar has a total of 1 drug patent out of which 0 drug patents have expired.
Vraylar was authorised for market use on 17 September, 2015.
Vraylar is available in capsule;oral dosage forms.
Vraylar can be used as treatment of schizophrenia with cariprazine; adjunctive therapy to antidepressants for the treatment of major depressive disorder; treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine.
The generics of Vraylar are possible to be released after 16 July, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 16, 2025 |
Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 September, 2015
Treatment: Treatment of schizophrenia with cariprazine; Adjunctive therapy to antidepressants for the treatment of major depressive disorder; Treatment of acute manic or mixed episodes associated with bipolar i ...
Dosage: CAPSULE;ORAL
VRAYLAR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic